David Scheinberg joins Galena's SAB
This article was originally published in Scrip
Galena Biopharma, a biotech company developing targeted oncology treatments, has appointed Dr David Scheinberg to its scientific advisory board. Dr Scheinberg is Memorial Sloan-Kettering Cancer Center's Vincent Astor chair, chair of the Molecular Pharmacology and Chemistry Program in the Sloan-Kettering Institute, and chair of the Experimental Therapeutics and the Nanotechnology Centers at Memorial Sloan-Kettering. In addition, Dr Scheinberg is professor of medicine and pharmacology at Weill-Cornell Medical College and serves on the boards of Progenics and Contrafect, and the scientific advisory boards of Actinium Pharmaceuticals, Ensysce Biosciences and OncoPep.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.